B+
Bull case
20%
Probability
Target price
$2.50
Analysis reference price unavailable
Analysis 2026-08-21 · RankAlpha Sentiment Codex
PROK
ProKidneyDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The completed accelerated-approval enrollment milestone and expected Q2 2027 eGFR-slope readout provide a credible clinical path, while reported liquidity of $181.6 million supports operations into mid-2027 [#SEC-8K-2026-08-10].
Posture
Defensive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite.
What can break
Binary clinical efficacy and regulatory risk around PROACT 1 and rilparencel.
Momentum
47
Value
41
Sentiment
49
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $1.70 · Bull $2.50 · Bear $0.80Analysis 2026-08-21; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-09 • Model: HYBRID_IC_RP
AI Memo
As of 2026-08-21 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-09
Investment thesis
As of 2026-09-09
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-09. Definitions
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $6.25
Why
Momentum47 · Δ7d -
Value41 · Δ7d 0.0
Sentiment49 · Δ7d -
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Sentiment remains the lead driver in the composite.
Contradictions & invalidation
- • Binary clinical efficacy and regulatory risk around PROACT 1 and rilparencel.
- • Cash and marketable securities declined to $181.6 million from $224.9 million in the prior quarter, while R&D spending increased [#SEC-8K-2026-08-10].
- • The investment remains highly binary: full enrollment, trial execution, regulatory progress, and the 2027 efficacy readout are unresolved.
Catalyst clock
2026-08-10
PROACT 1 accelerated-approval enrollment milestone
Lead driver: Sentiment · See AI snapshot
Momentum
47
9% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
41
28% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
+0.1
Sentiment
49
62% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade D. Momentum 47.3 / Value 41.2 / Sentiment 49.2
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-08-21. Scenario method
Most likely
B
Base case
55%
Probability
Target price
$1.70
Analysis reference price unavailable
Analysis 2026-08-21 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$0.80
Analysis reference price unavailable
Analysis 2026-08-21 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$427.73M
Beta
1.82
Shares Out
208.93M
P/E (TTM) · Derived
-4.0
P/S (TTM)
865.30
P/FCF (TTM) · Derived
-1.92
Rev YoY
-32.1%
EPS YoY
+20.4%
Gross Margin
-600.6%
Op Margin
-21664.5%
Net Debt
-$265.98M
Current Ratio
8.36
As of 2026-09-09 • Updated nightlySource: Internal modelMethods & Data